These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 29709968)

  • 21. Vaccinia virus strain LC16m8 defective in the B5R gene keeps strong protection comparable to its parental strain Lister in immunodeficient mice.
    Yokote H; Shinmura Y; Kanehara T; Maruno S; Kuranaga M; Matsui H; Hashizume S
    Vaccine; 2015 Nov; 33(45):6112-9. PubMed ID: 26241947
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of B virus glycoprotein antibodies induced by DNA immunization.
    Perelygina L; Patrusheva I; Zurkuhlen H; Hilliard JK
    Arch Virol; 2002 Nov; 147(11):2057-73. PubMed ID: 12417944
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protective immunity against herpes simplex virus (HSV) type 1 following oral administration of recombinant Salmonella typhimurium vaccine strains expressing HSV antigens.
    Karem KL; Bowen J; Kuklin N; Rouse BT
    J Gen Virol; 1997 Feb; 78 ( Pt 2)():427-34. PubMed ID: 9018066
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of a needle-free delivery platform for prime-boost immunization with DNA and modified vaccinia virus ankara vectors expressing herpes simplex virus 2 glycoprotein D.
    Meseda CA; Stout RR; Weir JP
    Viral Immunol; 2006; 19(2):250-9. PubMed ID: 16817767
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The potential of currently unavailable herpes virus vaccines.
    Rajčáni J; Bánáti F; Szenthe K; Szathmary S
    Expert Rev Vaccines; 2018 Mar; 17(3):239-248. PubMed ID: 29313728
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of herpes simplex virus glycoprotein D on antigen presenting cells infected with vaccinia recombinants and protective immunity.
    Wachsman M; Aurelian L; Hunter JC; Perkus ME; Paoletti E
    Biosci Rep; 1988 Aug; 8(4):323-34. PubMed ID: 3263886
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetically engineered poxviruses: a novel approach to the construction of live vaccines.
    Paoletti E; Weinberg RL; Davis SW; Davis M
    Vaccine; 1984 Sep; 2(3):204-8. PubMed ID: 6099648
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vaccine-induced serum immunoglobin contributes to protection from herpes simplex virus type 2 genital infection in the presence of immune T cells.
    Morrison LA; Zhu L; Thebeau LG
    J Virol; 2001 Feb; 75(3):1195-204. PubMed ID: 11152492
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human cytotoxic T cell clones directed against herpes simplex virus-infected cells. IV. Recognition and activation by cloned glycoproteins gB and gD.
    Zarling JM; Moran PA; Burke RL; Pachl C; Berman PW; Lasky LA
    J Immunol; 1986 Jun; 136(12):4669-73. PubMed ID: 2423598
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An attenuated LC16m8 smallpox vaccine: analysis of full-genome sequence and induction of immune protection.
    Morikawa S; Sakiyama T; Hasegawa H; Saijo M; Maeda A; Kurane I; Maeno G; Kimura J; Hirama C; Yoshida T; Asahi-Ozaki Y; Sata T; Kurata T; Kojima A
    J Virol; 2005 Sep; 79(18):11873-91. PubMed ID: 16140764
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of coexpression of IL-2 and herpes simplex virus proteins in recombinant vaccinia virus vectors on levels of induced immunity.
    Allen EM; Weir JP; Martin S; Mercadal C; Rouse BT
    Viral Immunol; 1990; 3(3):207-15. PubMed ID: 2175194
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recombinant vaccinia virus expressing the herpes simplex virus type 1 glycoprotein C protects mice against herpes simplex virus challenge.
    Weir JP; Bennett M; Allen EM; Elkins KL; Martin S; Rouse BT
    J Gen Virol; 1989 Oct; 70 ( Pt 10)():2587-94. PubMed ID: 2794972
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Syncytial Mutations Do Not Impair the Specificity of Entry and Spread of a Glycoprotein D Receptor-Retargeted Herpes Simplex Virus.
    Okubo Y; Uchida H; Wakata A; Suzuki T; Shibata T; Ikeda H; Yamaguchi M; Cohen JB; Glorioso JC; Tagaya M; Hamada H; Tahara H
    J Virol; 2016 Dec; 90(24):11096-11105. PubMed ID: 27707922
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monoclonal antibodies to the distinct antigenic sites on glycoproteins C and B and their protective abilities in herpes simplex virus infection.
    Bystrická M; Petríková M; Zatovicová M; Soláriková L; Kostolanský F; Mucha V; Russ G
    Acta Virol; 1997 Feb; 41(1):5-12. PubMed ID: 9199708
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficient production of recombinant glycoprotein D of herpes simplex virus type 2 in Pichia pastoris and its protective efficacy against viral challenge in mice.
    Wang M; Jiang S; Zhou L; Wang C; Mao R; Ponnusamy M
    Arch Virol; 2017 Mar; 162(3):701-711. PubMed ID: 27868164
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Virus-encoded b7-2 costimulation molecules enhance the protective capacity of a replication-defective herpes simplex virus type 2 vaccine in immunocompetent mice.
    Vagvala SP; Thebeau LG; Wilson SR; Morrison LA
    J Virol; 2009 Jan; 83(2):953-60. PubMed ID: 18987142
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dual Ligand Insertion in gB and gD of Oncolytic Herpes Simplex Viruses for Retargeting to a Producer Vero Cell Line and to Cancer Cells.
    Petrovic B; Leoni V; Gatta V; Zaghini A; Vannini A; Campadelli-Fiume G
    J Virol; 2018 Mar; 92(6):. PubMed ID: 29263257
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DNA vaccine-encoded glycoprotein B of HSV-1 fails to protect chronic morphine-treated mice against HSV-1 challenge.
    Jamali A; Roostaee MH; Soleimanjahi H; Ghaderi Pakdel F; Bamdad T
    Comp Immunol Microbiol Infect Dis; 2007 Mar; 30(2):71-80. PubMed ID: 17126902
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and immunogenicity of a glycoprotein D genital herpes vaccine in healthy girls 10-17 years of age: results from a randomised, controlled, double-blind trial.
    ; Abu-Elyazeed RR; Heineman T; Dubin G; Fourneau M; Leroux-Roels I; Leroux-Roels G; Richardus JH; Ostergaard L; Diez-Domingo J; Poder A; Van Damme P; Romanowski B; Blatter M; Silfverdal SA; Berglund J; Josefsson A; Cunningham AL; Flodmark CE; Tragiannidis A; Dobson S; Olafsson J; Puig-Barbera J; Mendez M; Barton S; Bernstein D; Mares J; Ratner P
    Vaccine; 2013 Dec; 31(51):6136-43. PubMed ID: 23850416
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8.
    Kidokoro M; Tashiro M; Shida H
    Proc Natl Acad Sci U S A; 2005 Mar; 102(11):4152-7. PubMed ID: 15753319
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.